Corporate Support
Sanofi-aventis, makers of Rilutek® (riluzole) tablets, is committed to helping patients
with ALS and their caregivers, and sponsors two patient assistance programs.
- The Rilutek Continuity Program provides ALS patients with important
pharmacy and insurance services.
- The Rilutek Patient Assistance Program provides an equal opportunity
for ALS patients to receive treatment.
We at Sanofi-aventis are committed to researching, developing, and bringing to market
new and innovative health care products so that we can fulfill our mission… Because
health matters.
Sanofi-aventis research is active in 7 major therapeutic areas:
- Central nervous system
- Cardiovascular diseases
- Thrombosis
- Metabolic disorders
- Oncology
- Internal medicine
- Vaccines
Log onto www.sanofi-aventis.com
for more information about the company’s research creativity and innovation in patient
health.
 |
 |
 |
|
|
Important Treatment Considerations
- Evaluate serum ALT levels every month during the first 3 months
of treatment, and every 3 months during the remainder of the first year. Thereafter,
serum ALT levels should be periodically evaluated more frequently in patients who
develop elevations. Rilutek should be discontinued if ALT levels increase to 5 times
ULN or if clinical jaundice develops.
- Advise patients about the potential for dizziness, vertigo, or
somnolence and not to drive or operate machinery until they have sufficient experience
on Rilutek.
- Advise patients to report any febrile illness; measure WBCs.
- Use Rilutek with caution in patients with concomitant liver insufficiency;
caution should be exercised when prescribing Rilutek to patients taking drugs that
are potentially hepatotoxic or highly protein bound:
- Interactions may also occur when riluzole is given concurrently
with agents that affect hepatic CYP 1A2 activity.*
|
|
|
 |
|
 |
|
|
|